Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome

NCT03094637 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

High Risk Myelodysplastic Syndrome
IPSS Risk Category Intermediate-1
Myelodysplastic Syndrome

Interventions

DRUG: Azacitidine
BIOLOGICAL: Pembrolizumab

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]